Theravance Biopharma Antibiotics, Inc. [clinicaltrials_resource:fa3e06e19319fe0c09a180728263afd3]
Principal Investigator [clinicaltrials_resource:0790550ef2dc10cdd9b1463e9ff29f46]Principal Investigator [clinicaltrials_resource:33a5d6304d02afdf28fb97566ead9b83]Maria Pecoraro, MD, MPH [clinicaltrials_resource:38ee9639a10346cc9f9833d4149741fc]Daniel M. Canafax, PharmD, FCCP [clinicaltrials_resource:3d1d4b4d55ce1a0f70221a3715111777]Maria Pecoraro, MD, MPH [clinicaltrials_resource:4a0904bdf2e40519bcd116c19ffcb47b]Maria Pecoraro, MD, MPH [clinicaltrials_resource:4be22e45e93bcfb263e591837f51a646]Jon Bruss [clinicaltrials_resource:73f5bab5524a41a51f37383e291674b1]Steven L Barriere, PharmD [clinicaltrials_resource:7e103c29ba39a4cfabe2e03993837a61]Jon Bruss [clinicaltrials_resource:8a402adc5b16af75b1c7dd8fc5bc2a31]Jon Bruss [clinicaltrials_resource:8cc2d8841e10ee863fa2a90c8cfce764]Oranee Daniels, M.D. [clinicaltrials_resource:941c3f53121fbe58c4504f8d7bd03f72]Daniel M Canafax, Pharm.D., FCCP [clinicaltrials_resource:ace074f83183bcf8a114c511ee459500]
affiliation [clinicaltrials_vocabulary:affiliation]
clinicaltrials:NCT00061633clinicaltrials:NCT00062647clinicaltrials:NCT00077675clinicaltrials:NCT00091819clinicaltrials:NCT00107952clinicaltrials:NCT00107978clinicaltrials:NCT00124020TD-1792 in Gram-positive Complicated Skin and Skin Structure Infection [clinicaltrials:NCT00442832]VIBATIV Pregnancy Registry [clinicaltrials:NCT01130324]A Study to Evaluate the Effect of Renal Function on the Biological Activity of Telavancin [clinicaltrials:NCT01238796]TD-1607 SAD Study in Healthy Subjects [clinicaltrials:NCT01791049]TD-1607 MAD Study in Healthy Subjects [clinicaltrials:NCT01949103]An Open-Label Study of the Pharmacokinetics of a Single Dose of Telavancin in Pediatric Subjects Aged 1 to 17 Years [clinicaltrials:NCT02013141]A Phase 3 Telavancin Staphylococcus Aureus Bacteremia Trial [clinicaltrials:NCT02208063]Telavancin Observational Use Registry (TOUR) [clinicaltrials:NCT02288234]
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
clinicaltrials:NCT00061633clinicaltrials:NCT00062647clinicaltrials:NCT00077675clinicaltrials:NCT00091819clinicaltrials:NCT00107952clinicaltrials:NCT00107978clinicaltrials:NCT00124020TD-1792 in Gram-positive Complicated Skin and Skin Structure Infection [clinicaltrials:NCT00442832]A Multiple Dose Study of TD-1211 in Healthy Volunteers and Patients With Opioid-Induced Constipation [clinicaltrials:NCT01040637]VIBATIV Pregnancy Registry [clinicaltrials:NCT01130324]A Study to Evaluate the Effect of Renal Function on the Biological Activity of Telavancin [clinicaltrials:NCT01238796]A Study to Assess the Safety, Tolerability and Clinical Activity of TD−1211 in Patients With Opioid-Induced Constipation [clinicaltrials:NCT01333540]A Study of TD-1211 in Subjects With Opioid-Induced Constipation (OIC) [clinicaltrials:NCT01401985]Phase 2 Study of TD-9855 to Treat Fibromyalgia [clinicaltrials:NCT01693692]TD-1211 IV/Oral Mass Balance Study [clinicaltrials:NCT01702194]TD-1607 SAD Study in Healthy Subjects [clinicaltrials:NCT01791049]TD-1607 MAD Study in Healthy Subjects [clinicaltrials:NCT01949103]An Open-Label Study of the Pharmacokinetics of a Single Dose of Telavancin in Pediatric Subjects Aged 1 to 17 Years [clinicaltrials:NCT02013141]A Phase 3 Telavancin Staphylococcus Aureus Bacteremia Trial [clinicaltrials:NCT02208063]Telavancin Observational Use Registry (TOUR) [clinicaltrials:NCT02288234]
source [clinicaltrials_vocabulary:source]
Theravance Biopharma Antibiotics, Inc. [clinicaltrials_resource:fa3e06e19319fe0c09a180728263afd3]
Bio2RDF identifier
fa3e06e19319fe0c09a180728263afd3
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:fa3e06e19319fe0c09a180728263afd3
organization [clinicaltrials_vocabulary:organization]
identifier
clinicaltrials_resource:fa3e06e19319fe0c09a180728263afd3
title
Theravance Biopharma Antibiotics, Inc.
@en
type
label
Theravance Biopharma Antibioti ...... e06e19319fe0c09a180728263afd3]
@en